Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOCARD
2024-517403-36-00Phase 4Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab and nivolumab in cancer (2 arms), sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoint: Evolution of left ventricular function measured by global longitudinal strain. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-517403-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517403-36-00.